Logo image of BMA.OL

BYGGMA ASA (BMA.OL) Stock Fundamental Analysis

OSL:BMA - Euronext Oslo - NO0003087603 - Common Stock - Currency: NOK

18.9  -0.3 (-1.56%)

Fundamental Rating

1

Overall BMA gets a fundamental rating of 1 out of 10. We evaluated BMA against 19 industry peers in the Building Products industry. BMA may be in some trouble as it scores bad on both profitability and health. BMA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BMA had negative earnings in the past year.
Of the past 5 years BMA 4 years were profitable.
Of the past 5 years BMA 4 years had a positive operating cash flow.
BMA.OL Yearly Net Income VS EBIT VS OCF VS FCFBMA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

The Return On Assets of BMA (-11.46%) is worse than 90.00% of its industry peers.
Looking at the Return On Equity, with a value of -36.58%, BMA is doing worse than 85.00% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 2.42%, BMA is doing worse than 75.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for BMA is below the industry average of 8.38%.
Industry RankSector Rank
ROA -11.46%
ROE -36.58%
ROIC 2.42%
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)6.04%
ROIC(5y)8.48%
BMA.OL Yearly ROA, ROE, ROICBMA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

BMA's Operating Margin of 1.57% is on the low side compared to the rest of the industry. BMA is outperformed by 80.00% of its industry peers.
BMA's Operating Margin has declined in the last couple of years.
BMA has a better Gross Margin (49.47%) than 70.00% of its industry peers.
BMA's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 1.57%
PM (TTM) N/A
GM 49.47%
OM growth 3Y-53.57%
OM growth 5Y-24.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
BMA.OL Yearly Profit, Operating, Gross MarginsBMA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

More info and screens

1

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMA is destroying value.
Compared to 1 year ago, BMA has about the same amount of shares outstanding.
Compared to 5 years ago, BMA has more shares outstanding
Compared to 1 year ago, BMA has a worse debt to assets ratio.
BMA.OL Yearly Shares OutstandingBMA.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BMA.OL Yearly Total Debt VS Total AssetsBMA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 2.05 indicates that BMA is not a great score, but indicates only limited risk for bankruptcy at the moment.
BMA has a worse Altman-Z score (2.05) than 65.00% of its industry peers.
A Debt/Equity ratio of 0.94 indicates that BMA is somewhat dependend on debt financing.
BMA's Debt to Equity ratio of 0.94 is on the low side compared to the rest of the industry. BMA is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Altman-Z 2.05
ROIC/WACC0.27
WACC8.86%
BMA.OL Yearly LT Debt VS Equity VS FCFBMA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

BMA has a Current Ratio of 0.75. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.75, BMA is not doing good in the industry: 90.00% of the companies in the same industry are doing better.
BMA has a Quick Ratio of 0.75. This is a bad value and indicates that BMA is not financially healthy enough and could expect problems in meeting its short term obligations.
BMA has a worse Quick ratio (0.40) than 90.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.75
Quick Ratio 0.4
BMA.OL Yearly Current Assets VS Current LiabilitesBMA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

2

3. Growth

3.1 Past

The earnings per share for BMA have decreased strongly by -647.91% in the last year.
The Revenue has grown by 69.16% in the past year. This is a very strong growth!
Measured over the past years, BMA shows a small growth in Revenue. The Revenue has been growing by 3.98% on average per year.
EPS 1Y (TTM)-647.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-249.65%
Revenue 1Y (TTM)69.16%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%279.35%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMA.OL Yearly Revenue VS EstimatesBMA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BMA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BMA.OL Price Earnings VS Forward Price EarningsBMA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMA.OL Per share dataBMA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40 50

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BYGGMA ASA

OSL:BMA (5/23/2025, 7:00:00 PM)

18.9

-0.3 (-1.56%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners3.19%
Ins Owner ChangeN/A
Market Cap1.32B
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.35
P/FCF N/A
P/OCF N/A
P/B 1.45
P/tB 1.48
EV/EBITDA N/A
EPS(TTM)-4.78
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS53.85
BVpS13.07
TBVpS12.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -11.46%
ROE -36.58%
ROCE 3.15%
ROIC 2.42%
ROICexc 2.49%
ROICexgc 2.52%
OM 1.57%
PM (TTM) N/A
GM 49.47%
FCFM N/A
ROA(3y)2.06%
ROA(5y)4.25%
ROE(3y)5.65%
ROE(5y)11.19%
ROIC(3y)6.04%
ROIC(5y)8.48%
ROICexc(3y)6.14%
ROICexc(5y)9.7%
ROICexgc(3y)6.2%
ROICexgc(5y)9.87%
ROCE(3y)8.16%
ROCE(5y)11.25%
ROICexcg growth 3Y-60.86%
ROICexcg growth 5Y-30.2%
ROICexc growth 3Y-60.74%
ROICexc growth 5Y-29.96%
OM growth 3Y-53.57%
OM growth 5Y-24.03%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.63%
F-ScoreN/A
Asset Turnover1.29
Health
Industry RankSector Rank
Debt/Equity 0.94
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.75
Quick Ratio 0.4
Altman-Z 2.05
F-ScoreN/A
WACC8.86%
ROIC/WACC0.27
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-647.91%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-249.65%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)69.16%
Revenue growth 3Y-2.58%
Revenue growth 5Y3.98%
Sales Q2Q%279.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y264.55%
EBIT growth 3Y-54.77%
EBIT growth 5Y-21.01%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A